Last updated on December 2017

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06687234 as Add-On Therapy to Infliximab in Active Ulcerative Colitis Subjects Who Are Not in Remission


Brief description of study

This is a phase 2a, randomized, double-blind, placebo-controlled, parallel group, multicenter study in subjects with active UC and a non-remission response to infliximab.

 

There will be up to 13 study visits, across the 12 weeks of treatment, along with 2 follow-up visits, at Weeks 16 and 22.

Ideal patients for this study will have a flexible schedule, as they will be required to come in for weekly study visits.

Clinical Study Identifier: TX155002

Contact Investigators or Research Sites near you

Start Over

Crystal Beaber, MA, CCRC

Gastroenterology Associates of Tidewater
Chesapeake, VA USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.